|
@ Isabartels #36 CV Therapeutics downgraded on `negative` FDA documents (CVTX) By Tomi Kilgore NEW YORK (CBS.MW) -- Analyst David Webber at First Albany downgraded CV Therapeutics (CVTX) to "neutral" from "buy," citing negative Food and Drug Administration briefing documents that suggest that its angina treatment Ranexa is unlikely to be approved without a "substantial" new clinical trial. The stock took a $3.68, or 22 percent dive to $13.08, and was the leading percentage loser listed on the Nasdaq National Market. "In the documents, the FDA appears to view Ranexa as modestly effective, but notes significant safety risks that are not offset by the product`s demonstrated benefits," Webber said in a note to clients. He feels the stock could trade down as low as the $10 to $13 level, but not as low as the USD 5.81, which is the company`s net cash value. |
|
| aus der Diskussion: | +++ CV Therapeutics Inc (CVTX) - Kurssturz +++ |
| Autor (Datum des Eintrages): | pokibeloki (09.12.03 23:52:55) |
| Beitrag: | 48 von 470 (ID:11562929) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |